1 Retinal Drugs and Biologics Market Overview
1.1 Product Overview and Scope of Retinal Drugs and Biologics
1.2 Retinal Drugs and Biologics Segment by Type
1.2.1 Global Retinal Drugs and Biologics Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Age Related Macular Degeneration
1.2.3 Diabetic Retinopathy
1.2.4 Ocular Inflammatory Disease (Uveitis)
1.2.5 Macular Hole
1.3 Retinal Drugs and Biologics Segment by Application
1.3.1 Global Retinal Drugs and Biologics Sales Comparison by Application: (2023-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Retinal Drugs and Biologics Market Size Estimates and Forecasts
1.4.1 Global Retinal Drugs and Biologics Revenue 2018-2030
1.4.2 Global Retinal Drugs and Biologics Sales 2018-2030
1.4.3 Retinal Drugs and Biologics Market Size by Region: 2018 Versus 2022 Versus 2030
2 Retinal Drugs and Biologics Market Competition by Manufacturers
2.1 Global Retinal Drugs and Biologics Sales Market Share by Manufacturers (2018-2023)
2.2 Global Retinal Drugs and Biologics Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Retinal Drugs and Biologics Average Price by Manufacturers (2018-2023)
2.4 Manufacturers Retinal Drugs and Biologics Manufacturing Sites, Area Served, Product Type
2.5 Retinal Drugs and Biologics Market Competitive Situation and Trends
2.5.1 Retinal Drugs and Biologics Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Retinal Drugs and Biologics Players Market Share by Revenue
2.5.3 Global Retinal Drugs and Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Retinal Drugs and Biologics Retrospective Market Scenario by Region
3.1 Global Retinal Drugs and Biologics Retrospective Market Scenario in Sales by Region: 2018-2023
3.2 Global Retinal Drugs and Biologics Retrospective Market Scenario in Revenue by Region: 2018-2023
3.3 North America Retinal Drugs and Biologics Market Facts & Figures by Country
3.3.1 North America Retinal Drugs and Biologics Sales by Country
3.3.2 North America Retinal Drugs and Biologics Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Retinal Drugs and Biologics Market Facts & Figures by Country
3.4.1 Europe Retinal Drugs and Biologics Sales by Country
3.4.2 Europe Retinal Drugs and Biologics Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Retinal Drugs and Biologics Market Facts & Figures by Region
3.5.1 Asia Pacific Retinal Drugs and Biologics Sales by Region
3.5.2 Asia Pacific Retinal Drugs and Biologics Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Retinal Drugs and Biologics Market Facts & Figures by Country
3.6.1 Latin America Retinal Drugs and Biologics Sales by Country
3.6.2 Latin America Retinal Drugs and Biologics Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Retinal Drugs and Biologics Market Facts & Figures by Country
3.7.1 Middle East and Africa Retinal Drugs and Biologics Sales by Country
3.7.2 Middle East and Africa Retinal Drugs and Biologics Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Retinal Drugs and Biologics Historic Market Analysis by Type
4.1 Global Retinal Drugs and Biologics Sales Market Share by Type (2018-2023)
4.2 Global Retinal Drugs and Biologics Revenue Market Share by Type (2018-2023)
4.3 Global Retinal Drugs and Biologics Price by Type (2018-2023)
5 Global Retinal Drugs and Biologics Historic Market Analysis by Application
5.1 Global Retinal Drugs and Biologics Sales Market Share by Application (2018-2023)
5.2 Global Retinal Drugs and Biologics Revenue Market Share by Application (2018-2023)
5.3 Global Retinal Drugs and Biologics Price by Application (2018-2023)
6 Key Companies Profiled
6.1 ALLERGAN
6.1.1 ALLERGAN Corporation Information
6.1.2 ALLERGAN Description and Business Overview
6.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.1.4 ALLERGAN Retinal Drugs and Biologics Product Portfolio
6.1.5 ALLERGAN Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Corporation Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AbbVie Retinal Drugs and Biologics Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 Alimera Sciences
6.3.1 Alimera Sciences Corporation Information
6.3.2 Alimera Sciences Description and Business Overview
6.3.3 Alimera Sciences Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Alimera Sciences Retinal Drugs and Biologics Product Portfolio
6.3.5 Alimera Sciences Recent Developments/Updates
6.4 Janssen Biotech
6.4.1 Janssen Biotech Corporation Information
6.4.2 Janssen Biotech Description and Business Overview
6.4.3 Janssen Biotech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Janssen Biotech Retinal Drugs and Biologics Product Portfolio
6.4.5 Janssen Biotech Recent Developments/Updates
6.5 Swedish Orphan Biovitrum
6.5.1 Swedish Orphan Biovitrum Corporation Information
6.5.2 Swedish Orphan Biovitrum Description and Business Overview
6.5.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio
6.5.5 Swedish Orphan Biovitrum Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Roche Retinal Drugs and Biologics Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Genzyme
6.8.1 Genzyme Corporation Information
6.8.2 Genzyme Description and Business Overview
6.8.3 Genzyme Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Genzyme Retinal Drugs and Biologics Product Portfolio
6.8.5 Genzyme Recent Developments/Updates
6.9 Genentech
6.9.1 Genentech Corporation Information
6.9.2 Genentech Description and Business Overview
6.9.3 Genentech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Genentech Retinal Drugs and Biologics Product Portfolio
6.9.5 Genentech Recent Developments/Updates
6.10 OCULAR THERAPEUTIX
6.10.1 OCULAR THERAPEUTIX Corporation Information
6.10.2 OCULAR THERAPEUTIX Description and Business Overview
6.10.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.10.4 OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio
6.10.5 OCULAR THERAPEUTIX Recent Developments/Updates
6.11 Bausch & Lomb
6.11.1 Bausch & Lomb Corporation Information
6.11.2 Bausch & Lomb Retinal Drugs and Biologics Description and Business Overview
6.11.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Bausch & Lomb Retinal Drugs and Biologics Product Portfolio
6.11.5 Bausch & Lomb Recent Developments/Updates
6.12 UCBCares
6.12.1 UCBCares Corporation Information
6.12.2 UCBCares Retinal Drugs and Biologics Description and Business Overview
6.12.3 UCBCares Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2018-2023)
6.12.4 UCBCares Retinal Drugs and Biologics Product Portfolio
6.12.5 UCBCares Recent Developments/Updates
7 Retinal Drugs and Biologics Manufacturing Cost Analysis
7.1 Retinal Drugs and Biologics Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Retinal Drugs and Biologics
7.4 Retinal Drugs and Biologics Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Retinal Drugs and Biologics Distributors List
8.3 Retinal Drugs and Biologics Customers
9 Retinal Drugs and Biologics Market Dynamics
9.1 Retinal Drugs and Biologics Industry Trends
9.2 Retinal Drugs and Biologics Market Drivers
9.3 Retinal Drugs and Biologics Market Challenges
9.4 Retinal Drugs and Biologics Market Restraints
10 Global Market Forecast
10.1 Retinal Drugs and Biologics Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Retinal Drugs and Biologics by Type (2023-2030)
10.1.2 Global Forecasted Revenue of Retinal Drugs and Biologics by Type (2023-2030)
10.2 Retinal Drugs and Biologics Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Retinal Drugs and Biologics by Application (2023-2030)
10.2.2 Global Forecasted Revenue of Retinal Drugs and Biologics by Application (2023-2030)
10.3 Retinal Drugs and Biologics Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Retinal Drugs and Biologics by Region (2023-2030)
10.3.2 Global Forecasted Revenue of Retinal Drugs and Biologics by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
